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Low protein synthesis is a feature of somatic stem
cells that promotes regeneration in multiple tissues.
Modest increases in protein synthesis impair stem
cell function, but the mechanisms by which this oc-
curs are largely unknown.Wedetermine that lowpro-
tein synthesiswithin hematopoietic stemcells (HSCs)
is associated with elevated proteome quality in vivo.
HSCs contain less misfolded and unfolded proteins
than myeloid progenitors. Increases in protein syn-
thesis cause HSCs to accumulate misfolded and
unfolded proteins. To test how proteome quality af-
fects HSCs, we examine Aarssti/sti mice that harbor
a tRNA editing defect that increases amino acid mis-
incorporation. Aarssti/sti mice exhibit reduced HSC
numbers, increased proliferation, and diminished se-
rial reconstituting activity. Misfolded proteins over-
whelm the proteasome within Aarssti/sti HSCs, which
is associatedwith increasedc-Mycabundance.Dele-
tion of oneMyc allele partially rescues serial reconsti-
tution defects in Aarssti/sti HSCs. Thus, HSCs are
dependent on low protein synthesis to maintain pro-
teostasis, which promotes their self-renewal.INTRODUCTION
Adult hematopoietic stem cells (HSCs) synthesize less protein
per hour than most other hematopoietic progenitors. This does
not simply reflect HSC quiescence because dividing HSCs
also have lower rates of protein synthesis than dividing restricted
progenitors (Signer et al., 2014). Low protein synthesis is neces-
sary for HSCmaintenance, as genetic changes that modestly in-
crease protein synthesis impair HSC function (Goncalves et al.,
2016; Signer et al., 2014, 2016). Somatic stem cells in multiple
other adult tissues also have relatively low rates of protein syn-
thesis, and this is often necessary for stem cell maintenance
(Blanco et al., 2016; Llorens-Bobadilla et al., 2015; Sanchez
et al., 2016; Zismanov et al., 2016). This raises a fundamentalThis is an open access article under the CC BY-Nquestion of why low protein synthesis is necessary for stem
cell maintenance and tissue regeneration.
Translation is the most error-prone step in gene expression.
Translational errors can lead to protein misfolding and the forma-
tion of toxic aggregates. High rates of protein synthesis can in-
crease amino acid misincorporation (Drummond and Wilke,
2009). Reducing translation decreases the synthesis of defective
translational products and promotes the clearance of misfolded
proteins (Sherman and Qian, 2013). Based on these observa-
tions, we hypothesized that low protein synthesis could promote
HSC maintenance and function by enhancing proteome quality,
which we define as limiting the abundance of mistranslated,
unfolded, and/or misfolded proteins. In this study, we set out
to examine the effect of protein synthesis rates on proteome
quality within HSCs in vivo and to test the consequences of
reducing protein quality on HSC function.RESULTS
HSCs Contain Less Ubiquitylated and Unfolded Protein
Than Myeloid Progenitors
To assess proteome quality within hematopoietic stem and pro-
genitor cells, we measured the abundance of ubiquitylated
protein by western blot. Ubiquitylated protein includes an abun-
dance of mistranslated or damaged proteins that misfold and
are targeted for degradation (Duttler et al., 2013; Kim et al.,
2011; Wang et al., 2013). As a consequence, ubiquitylated pro-
tein is widely used to assess the abundance of misfolded and
unfolded proteins (Kim et al., 2011; Lee et al., 2006; Schubert
et al., 2000). To obtain enough cells for western blot analyses,
we typically pooled CD150+CD48LineageSca-1+c-kit+
(CD150+CD48LSK) HSCs (Kiel et al., 2005) and
CD150CD48LSK multipotent progenitors (MPPs) (Oguro
et al., 2013). HSCs and this population ofMPPs (which are some-
times referred to as short-term HSCs) are very similar in terms of
their gene expression profile (Signer et al., 2016), cell cycle status
(Oguro et al., 2013), protein synthesis rate (Signer et al., 2014),
and metabolism (Agathocleous et al., 2017). CD48LSK HSCs/
MPPs contained considerably less ubiquitylated protein and
less LysK48-linkage specific polyubiquitylated protein (which
preferentially targets substrates for degradation) than equalCell Reports 30, 69–80, January 7, 2020 ª 2019 The Author(s). 69
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. HSCs Depend upon Low Protein Synthesis to Maintain Proteome Quality
(A) Western blot examining ubiquitylated protein in 3 3 104 HSCs/MPPs, CMPs, GMPs, and MEPs (one of >5 blots).
(B) Flow cytometry analysis showing ubiquitylated protein content relative to HSCs (n = 11 mice).
(C) Representative histograms of ubiquitylated protein content in HSCs, CMPs, GMPs, and MEPs.
(D) Cell volume of HSCs, CMPs, GMPs, and MEPs (nR 34 cells/population).
(E) Representative gel showing total protein content following SYPRO Ruby staining in HSCs/MPPs, CMPs, GMPs, and MEPs (one of 4 blots).
(F) Total protein content relative to HSCs (n = 4 experiments).
(G) Ubiquitylated protein relative to total protein content in HSCs, CMPs, GMPs, and MEPs (from B and E).
(H) Diagram showing that TMI fluoresces when it binds to free cysteine thiols in unfolded proteins.
(I) Relative TMI fluorescence in bone marrow cells after a 4-h incubation at 37C or 42C (n = 8 mice).
(J) Total protein content in bone marrow cells after a 4-h incubation at 37C or 42C (n = 3 mice).
(K) TMI fluorescence in bone marrow cells from mice treated 18 h earlier with bortezomib (BZ) or vehicle (DMSO) (n = 6 mice/treatment).
(L) Relative TMI fluorescence in HSCs and progenitors (n = 11 mice).
(M) OP-Puro incorporation by HSCs, CMPs, GMPs, and MEPs in vivo (n = 4 mice).
(N) Diagram representing effects on HSC protein synthesis in wild-type (Ptenfl/fl;Rpl24+/+), Pten-deficient (Mx1-Cre+Ptenfl/fl;Rpl24+/+), and
Mx1-Cre+;Ptenfl/fl;Rpl24Bst/+ mice.
(legend continued on next page)
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numbers of common myeloid progenitors (CMPs), granulocyte
macrophage progenitors (GMPs) and megakaryocyte erythroid
progenitors (MEPs) (Akashi et al., 2000) isolated from the bone
marrow of young adult mice (Figures 1A and S1A).
Unfortunately, it is not possible to develop western blots with
all ubiquitylated protein within the linear range of exposure,
which precludes accurate quantification. To circumvent this lim-
itation, we quantified ubiquitylated protein by intracellular flow
cytometry using an antibody that preferentially recognizes
polyubiquitin chains and exhibits no immunoreactivity with free
ubiquitin (Markmiller et al., 2019). HSCs contained significantly
less ubiquitylated protein than CMPs (47%; p < 0.01),
GMPs (157%; p < 0.001), and MEPs (57%; p < 0.001) (Figures
1B and 1C).
Differences in ubiquitylated protein could not be explained by
differences in cell volume, total protein abundance, or protea-
some activity. Cell volume was similar between HSCs and
CMPs (Figure 1D) despite HSCs having significantly less ubiqui-
tylated protein (Figure 1B). Restricted progenitors also contained
similar amounts of total protein as HSCs (Figure 1E and 1F), and
HSCs had significantly less ubiquitylated protein than restricted
progenitors even when normalized to total protein abundance
(Figure 1G). HSCs also exhibited much less proteasome activity
than CMPs (10-fold; p < 0.001), GMPs (132-fold; p < 0.001)
(Signer et al., 2016), and MEPs (6.5-fold; p < 0.01) (Figure 3F).
Although ubiquitylated protein is used as a surrogate to quan-
tify misfolded and unfolded proteins (Lee et al., 2006; Sontag
et al., 2014; Vilchez et al., 2012), not all ubiquitylated protein
arises from misfolding events. We thus sought an orthogonal
assay to measure protein quality. Tetraphenylethene maleimide
(TMI) is a cell-permeable dye that fluoresces upon binding to
cysteine thiols (Chen et al., 2017). The free thiol side chains of
non-disulphide-bonded hydrophobic cysteines are typically
buried within the core of globular proteins (Marino and Glady-
shev, 2010) but can be exposed in unfolded proteins (Figure 1H).
We adapted TMI to quantify unfolded proteins within single he-
matopoietic cells by flow cytometry. Hematopoietic cells treated
with TMI exhibited a clear increase in fluorescence relative to un-
treated controls (Figure S1B). Although glutathione represents a
major pool of non-protein thiols within cells, it does not induce
TMI fluorescence (Chen et al., 2017). Furthermore, glutathione
levels do not significantly differ between HSCs and restricted
progenitors (Agathocleous et al., 2017).
To validate TMI fluorescence as a reporter of unfolded protein
accumulation in hematopoietic cells, we performed several inde-
pendent experiments. First, we assessed the effect of heat
shock, which induces protein unfolding (Morimoto, 2011), on
TMI fluorescence in bone marrow cells. Bone marrow cells incu-
bated at 42C for 4 h exhibited a 22% increase in TMI fluores-
cence relative to an aliquot of the same cells incubated at
37C (Figures 1I and S1B; p < 0.05). Heat-shocked bone marrow
cells had statistically equivalent amounts of total protein(O) Western blot examining ubiquitylated protein in 8.5 3 103 HSCs/MPPs from
mice (one of 3 blots).
(P) TMI fluorescence in wild-type, Mx1-Cre+;Ptenfl/fl;Rpl24+/+, and Mx1-Cre+;Pte
Data represent mean ± standard deviation. Statistical significance was assesse
comparisons test relative to HSCs (B, D, F, G, L, M, and P). *p < 0.05; **p < 0.01compared to bone marrow cells incubated at 37C (Figure 1J),
indicating that differences in TMI fluorescence do not simply
reflect differences in total protein abundance. Next, because
unfolded proteins are primarily degraded by the proteasome,
we assessed the effects of proteasome inhibition on TMI fluores-
cence in vivo. Bone marrow cells isolated frommice treated with
the proteasome inhibitor bortezomib exhibited a30% increase
in TMI fluorescence compared to cells from vehicle-treated con-
trols (Figures 1K and S1C; p < 0.05). Finally, we compared levels
of ubiquitylated protein within TMIlow (lowest quartile of TMI fluo-
rescence), TMIhigh (highest quartile of TMI fluorescence), and un-
fractionated bone marrow cells by western blot. TMIlow bone
marrow cells contained less ubiquitylated protein than unfractio-
nated bone marrow cells, which in turn contained less ubiquity-
lated protein than TMIhigh bone marrow cells (Figure S1D). These
data suggest that TMI fluorescence accurately reflects the
amount of unfolded proteins within primary hematopoietic cells.
Themean fluorescence intensity of TMI was significantly lower
in HSCs than CMPs (32%; p < 0.01), GMPs (25%; p < 0.05), and
MEPs (48%; p < 0.01) (Figures 1L and S1E–S1K). Although these
differences appear rather modest, the increase in TMI fluores-
cence in restricted progenitors compared to HSCs was similar
or greater in magnitude to that observed in bone marrow cells
following either heat shock (Figure 1I) or bortezomib administra-
tion (Figure 1K), which are both treatments that significantly
disrupt proteostasis. Overall, these data suggest that HSCs
contain significantly elevated proteome quality compared to
restricted myeloid progenitors in vivo.
Increasing Protein Synthesis Reduces Protein Quality
within HSCs In Vivo
Adult HSCs exhibit unusually low protein synthesis compared to
other hematopoietic cells (Figure 1M; Hidalgo San Jose and
Signer, 2019; Signer et al., 2014). Translation is the most error-
prone step in gene expression, and 10%–30% of all newly syn-
thesized proteins are ubiquitylated and targeted for degradation
(Lykke-Andersen and Bennett, 2014; Schubert et al., 2000). This
raises the question of whether low protein synthesis in HSCs
contributes to their reduced abundance of ubiquitylated and
unfolded protein in vivo.
To test if increasing protein synthesis reduces proteome qual-
ity within HSCs, we took advantage of two genetic mouse
models that modestly alter protein synthesis rates within HSCs
in vivo. Conditional deletion of Pten from adult hematopoietic
cells in Mx1-Cre;Ptenfl/fl mice leads to hyperactivation of the
PI3K andmTor signaling pathways, which increases protein syn-
thesis by 30% in HSCs (Signer et al., 2014). Introduction of a
ribosomal mutation (Rpl24Bst/+) (Oliver et al., 2004) functionally
blocks this increase in protein synthesis within Pten-deficient
HSCs without reducing hyperactivation of the downstream
signaling pathways (Figure 1N; Signer et al., 2014). Increased
protein synthesis within Pten-deficient HSCs was accompaniedPtenfl/fl;Rpl24+/+, Mx1-Cre+Ptenfl/fl;Rpl24+/+, and Mx1-Cre+;Ptenfl/fl; Rpl24Bst/+
nfl/fl;Rpl24Bst/+ mice (n = 3–4 mice/genotype).
d using a Student’s t test (I–K) or an ANOVA followed by Dunnett’s multiple
; ***p < 0.001.
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by an accumulation of ubiquitylated (Figure 1O) and unfolded
protein (Figure 1P; 30%; p < 0.05) relative to controls.
Rpl24Bst/+, which blocks the increase in protein synthesis (Signer
et al., 2014), also blocked the increase in ubiquitylated and
unfolded protein in Pten-deficient HSCs (Figures 1O and 1P).
These data indicate that increased protein synthesis reduces
protein quality within HSCs in vivo and suggests that HSCs
depend upon low protein synthesis to maintain the integrity of
their proteome.
Defects in tRNA Editing Preferentially Impair HSC Self-
Renewal
We previously demonstrated that conditional deletion of Pten
increases protein synthesis and severely impairs HSC func-
tion. Blocking the increase in protein synthesis with the
Rpl24Bst/+ mutation largely rescues the function of Pten-defi-
cient HSCs (Signer et al., 2014). These data indicate that
increased protein synthesis impairs HSC function. Consistent
with these observations, other genetic interventions that
modestly increase protein synthesis within HSCs, such as
deletion of Eif4ebp1 and Eif4ebp2 (Signer et al., 2016) or dele-
tion of Angiogenin (Goncalves et al., 2016), also impair HSC
function.
Given that increased protein synthesis impairs HSC function
and reduces proteome quality (Figures 1O and 1P), it raised
the question of whether the accumulation of misfolded and
unfolded proteins contributes to HSC dysfunction. To test this,
we sought amousemodel that could decouple increased protein
synthesis and reduced protein quality. Aarssti/sti mice harbor a
mutation in the alanyl-tRNA synthetase that causes a tRNA edit-
ing defect that increases amino acid misincorporation at alanine
residues, which can lead to an accumulation of mistranslated
and ubiquitylated proteins within slowly and non-dividing cells
(Lee et al., 2006). Aarssti/sti mice exhibit some skin and hair
texture defects as well as age-related neurological defects
(Lee et al., 2006). Despite these defects,Aarssti/sti mice are other-
wise grossly normal and survive into adulthood. Aarssti/sti HSCs
had an 18% increase in ubiquitylated protein compared to litter-
mate control HSCs (Figures 2A and 2B; p < 0.01). Notably, the
accumulation of ubiquitylated protein inAarssti/sti HSCs occurred
without significant changes in overall protein synthesisFigure 2. A tRNA Editing Defect that Reduces Proteome Quality Impai
(A) Western blot examining ubiquitylated protein in 2.5 3 104 wild-type (+/+) and
(B) Flow cytometry analysis showing ubiquitylated protein content in Aarssti/sti (st
(C) OP-Puro incorporation by wild-type (+/+) and Aarssti/sti (sti/sti) HSCs and pro
(D) Bone marrow cellularity (BM; 1 femur and 1 tibia) in wild-type (+/+) and Aarss
(E) Frequency of HSCs in wild-type (+/+) and Aarssti/sti (sti/sti) bone marrow (n =
(F and G) Absolute number of HSCs in the bone marrow (1 femur and 1 tibia; F) an
(H–J) Frequency of CMPs (H), GMPs (I), and MEPs (J) in wild-type (+/+) and Aars
(K) Frequency of colony-forming unit (CFU) progenitors in wild-type (+/+) and Aa
(L) Diagram showing HSC transplantation strategy.
(M) Donor cell engraftment when 10 HSCs from wild-type (+/+) and Aarssti/sti (sti/
irradiated mice. Total hematopoietic cell, B cell, T cell, and myeloid cell engraftm
(N) Donor cell engraftment in secondary recipients (n = 2 donors and 8–9 total re
(O) Frequency of secondary recipients in (N) that exhibited long-term (16-week)
myeloid cells).
Data represent mean ± standard deviation (B–K) or standard error of the mean
Fisher’s exact test (O). *p < 0.05; **p < 0.01; ***p < 0.001.(Figure 2C), cell size (Figure S2A) or proteasome activity
(Figure 3I). Furthermore, the increase in ubiquitylated protein
within Aarssti/sti HSCs was within the physiological range
observed within restricted progenitors (Figure S3A), making
Aarssti/sti HSCs more similar to other hematopoietic cells. These
data establish Aarssti/sti mice as a model to study the effects of a
physiological decline in protein quality in vivo that is independent
of changes in protein synthesis rate.
To assess the effects of reduced protein quality on hematopoi-
esis, we analyzed 8-week-old Aarssti/sti and littermate control
mice. Aarssti/sti mice had normal bone marrow cellularity (Fig-
ure 2D) but significantly reduced spleen cellularity (Figure S2I)
compared to controls. The frequency and absolute numbers of
HSCs were significantly reduced by 40% in the bone marrow
of Aarssti/sti mice (Figures 2E and 2F; p < 0.01). The decline in
HSCs was not due to mobilization to the spleen, as Aarssti/sti
mice did not exhibit an increase in spleen HSCs (Figure 2G). In
contrast to HSCs, the frequencies of CMPs, GMPs, MEPs,
CD71+Ter119+ erythroid progenitors, CD11b+Gr1+ myeloid
cells, pro-B cells, pre-B cells, IgM+ B cells, CD4+ T cells, and
CD8+ T cells were unchanged in the bone marrow and spleen
of Aarssti/sti mice compared to controls (Figures 2H–2J and
S2B–S2P). The frequency of colony-forming progenitors was
also unchanged inAarssti/sti mice (Figure 2K). These data indicate
that reduced protein quality in Aarssti/sti mice impairs the mainte-
nance of HSCs but does not significantly impact the mainte-
nance of restricted hematopoietic progenitors.
To test if reduced protein quality impairs HSC function, we
performed serial long-term reconstitution assays. We competi-
tively transplanted 10 CD150+CD48LSK HSCs from Aarssti/sti
or littermate control mice (CD45.2+) together with 2 3 105 wild-
type congenic (CD45.1+) bone marrow cells into lethally
irradiatedmice (CD45.1+) (Figure 2L). Overall, long-term hemato-
poietic reconstitution from Aarssti/sti HSCs was statistically indis-
tinguishable from controls in primary recipients (Figure 2M). After
16 weeks, 3 3 106 bone marrow cells from primary recipient
mice were serially transplanted into lethally irradiated mice. Sec-
ondary recipients of Aarssti/sti HSCs exhibited significantly less
donor cell reconstitution after transplantation (Figure 2N). None
(0/8) of the secondary recipients of Aarssti/sti HSCs exhibited
long-term multilineage reconstitution compared to 67% (6/9) ofrs HSC Self-Renewal
Aarssti/sti (sti/sti) HSCs/MPPs, CMPs, GMPs, and MEPs (one of 2 blots).
i/sti) relative to wild-type (+/+) HSCs (n = 4 mice/genotype).
genitor cells in vivo (n = 3 mice/genotype).
ti/sti (sti/sti) mice (n = 6 mice/genotype).
6 mice/genotype).
d spleen (G) of wild-type (+/+) and Aarssti/sti (sti/sti) mice (n = 6 mice/genotype).
sti/sti (sti/sti) bone marrow (n = 6 mice/genotype).
rssti/sti (sti/sti) bone marrow (n = 4 mice/genotype).
sti) mice were transplanted with 2 3 105 recipient-type bone marrow cells into
ent is shown (n = 4 donors and 14–21 total recipients/genotype).
cipients/genotype).
multilineage reconstitution (R0.5% donor derived peripheral blood B, T, and
(M and N). Statistical significance was assessed using a Student’s t test or a
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Figure 3. Accumulation of Ubiquitylated Protein Overwhelms the Proteasome in Aarssti/sti HSCs, Leading to c-Myc Stabilization
(A) Heatmap showing 94 differentially expressed transcripts (R2-fold change; padj < 0.1) up- (red) or downregulated (blue) between wild-type (+/+) and Aarssti/sti
(sti/sti) HSCs (n = 3 experiments/genotype).
(B) Gene set enrichment analysis demonstrating no significant activation of the UPRER in Aarssti/sti HSCs.
(C) Western blot examining phosphorylated (Ser51)-Eif2a in 2 3 104 wild-type (+/+) and Aarssti/sti (sti/sti) HSCs/MPPs.
(D) Frequency of Annexin V+ HSCs in wild-type (+/+) and Aarssti/sti (sti/sti) (n = 3 mice/genotype).
(E) Diagram of the proteostasis network.
(F) Proteasome activity in 5 3 103 HSCs/MPPs, CMPs, GMPs, and MEPs (n = 5–9 replicates in 4 experiments). Data are shown in relative luminescence units
(RLUs).
(G) Representative histogram showing GFP expression in UbG76V-GFP HSCs/MPPs in vitro treated for 18 h with (gray) or without (black) BZ.
(H) Frequency of HSCs that are GFP+ in UbG76V-GFP (+/+) and UbG76V-GFP;Aarssti/sti (sti/sti) bone marrow (n = 4-5 mice/genotype).
(I) Relative proteasome activity in wild-type (+/+) and Aarssti/sti (sti/sti) HSCs/MPPs (n = 9 replicates in 3 experiments).
(J) Number of HSCs in the bone marrow (1 femur and 1 tibia) in mice treated with BZ or vehicle (DMSO) (n = 5–6 mice/treatment).
(K) Frequency of wild-type (+/+) and Aarssti/sti (sti/sti) HSCs that incorporated BrdU after a 72-h pulse in vivo (n = 6-8 mice/genotype).
(L andM)Western blot examining c-Myc protein in 104 HSCs/MPPs (L) or 1.83 104 CMPs, GMPs andMEPs (M) isolated fromwild-type (+/+) andAarssti/sti (sti/sti)
mice (one of 2 (L) or 3 (M) blots).
(legend continued on next page)
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controls (Figure 2O; p < 0.01). These data indicate that Aarssti/sti
HSCs have impaired self-renewal potential in vivo.
We next sought to determinewhether reduced proteome qual-
ity preferentially impaired HSC function or whether it also
impaired the function of restricted progenitors. In contrast to
HSCs, we observed no significant increase in ubiquitylated pro-
tein among Aarssti/sti myeloid progenitors (Figures S3A–S3D).
This observation is consistent with previous reports that rapidly
dividing cells efficiently dilute out misfolded proteins (Lee et al.,
2006). Because Aarssti/sti myeloid progenitors do not accumulate
more ubiquitylated proteins than controls, we are precluded
from making direct conclusions on the effect of reduced protein
quality within those populations. We thus tested whether
CD150CD48LSK MPPs (short-term HSCs), a progenitor cell
population with similar cycling kinetics as HSCs (Oguro et al.,
2013), would be susceptible to an accumulation of ubiquitylated
proteins. Indeed, similar to HSCs, Aarssti/sti MPPs exhibited a
significant 16% increase in ubiquitylated protein compared
to controls (Figure S3E; p < 0.05). However, in contrast to
HSCs, we observed no significant change in MPP frequency
(Figure S3F). To test MPP function, we competitively trans-
planted 50 Aarssti/sti or control MPPs into irradiated mice
(Figure S3G). Levels of reconstitution by Aarssti/sti MPPs were
indistinguishable from controls (Figure S3H). Although HSC de-
fects largely appeared during serial transplantation, it is not
possible to perform secondary transplants with MPPs because
they lack serial reconstituting activity. Nevertheless, these data
suggest that HSCs are particularly sensitive to disruptions in pro-
teostasis, as modest declines in protein quality preferentially
impair HSC self-renewal.Accumulation ofMisfolded Proteins Overwhelms and/or
Impairs the Proteasome in HSCs
An accumulation of misfolded and unfolded proteins can acti-
vate proteotoxic stress response pathways, including the endo-
plasmic reticulum unfolded protein response (UPRER) (Walter
and Ron, 2011). Basal activity of the UPRER can promote HSC
survival and engraftment (Chapple et al., 2018; Liu et al., 2019;
van Galen et al., 2018). Under more severe stress conditions,
activation of the UPRER can induce apoptosis within HSCs (van
Galen et al., 2014) and fetal HSC self-renewal depends upon
bile acids to suppress UPRER activation (Sigurdsson et al.,
2016). This raised the question of whether the reduced HSC
number in Aarssti/sti mice was a consequence of activation of
the UPRER and increased cell death. To test this, we performed
RNA sequencing on Aarssti/sti and control HSCs (Figure 3A) and
looked for changes in the expression of gene sets related to the
UPRER. We observed no significant changes in the expression of
UPRER-related gene sets in Aarssti/sti compared to control HSCs
(Figure 3B). Consistent with this observation, Aarssti/sti HSCs did
not exhibit increased abundance of phosphorylated (Ser51)
Eif2a (Figure 3C), which is one marker of UPRER activation (Har-(N) Myc expression normalized to b-Actin in wild-type (+/+) and Aarssti/sti (sti/sti)
(O) Fbxw7 expression in wild-type (+/+) and Aarssti/sti (sti/sti) HSCs (n = 3/genoty
Data represent mean ± standard deviation. Statistical significance was assesse
Dunnett’s test relative to HSCs/MPPs (F). *p < 0.05; **p < 0.01; ***p < 0.001.ding et al., 1999). In addition, there was no significant difference
in the frequency of Annexin V+ HSCs between Aarssti/sti and con-
trol mice (Figure 3D), indicating that reduced HSC numbers in
Aarssti/sti mice are not due to increased cell death.
In the absence of detectable UPRER activation, we sought to
uncover other potential mechanisms contributing to Aarssti/sti
HSC dysfunction. Proteostasis, in addition to protein biogenesis,
is maintained by an integrated network of physiological mecha-
nisms that promote protein folding, repair, and degradation
(Labbadia and Morimoto, 2015; Figure 3E). Previous work has
demonstrated that overexpression of aggregation-prone pro-
teins can overwhelm and/or impair the ubiquitin proteasome
system in HEK293 cells (Bence et al., 2001). Because HSCs
exhibited less proteasome activity than restricted progenitors
(Figure 3F), we hypothesized that an accumulation of misfolded
proteins might overwhelm the capacity of the proteasome within
HSCs to efficiently degrade all ubiquitylated substrates.
To test this, we used UbG76V-GFP proteasome reporter mice
(Lindsten et al., 2003). UbG76V-GFP mice ubiquitously express
GFP that is fused to a constitutive degradation signal. GFP tran-
scripts can be detected in various tissues, but no GFP fluores-
cence is detected because the protein is rapidly degraded by
the proteasome. However, administration of a proteasome inhib-
itor leads to robust GFP fluorescence (Figure 3G; Lindsten et al.,
2003). Similar to other cell types, UbG76V-GFP HSCs did not ex-
press significant GFP fluorescence in vivo (Figure 3H). We
crossed UbG76V-GFP mice to Aarssti/sti mice and assessed
GFP expression within HSCs. Strikingly, we observed a signifi-
cant accumulation of GFP+ HSCs within UbG76V-GFP;Aarssti/sti
mice (Figure 3H; p < 0.01), and this was not due to a reduction
in proteasome activity (Figure 3I). These data indicate that the
proteasome can become overwhelmed and/or impaired when
misfolded proteins accumulate within HSCs.
To test if insufficient proteasome activity impairs HSC main-
tenance, we treated mice with bortezomib for 3 consecutive
days and assessed HSC numbers in the bone marrow on day
4. Mice treated with bortezomib exhibited a 50% reduction
in HSCs compared to vehicle (DMSO)-treated controls (Fig-
ure 3J; p < 0.01). The bortezomib-mediated decline in HSCs
was similar to the decline in HSCs observed within Aarssti/sti
mice (Figure 2F). These data indicate that impaired proteasome
activity impairs HSC maintenance and suggest that the decline
in Aarssti/sti HSCs may be caused by their overwhelmed/
impaired proteasome.Accumulation of Misfolded Proteins Is Associated with
c-Myc Accumulation in HSCs
In addition to regulating proteostasis, the ubiquitin proteasome
system post-translationally regulates the abundance of multiple
proteins that affect diverse cellular functions, including HSC fate
(Moran-Crusio et al., 2012). As a consequence, we wondered
if overwhelming the proteasome might lead to stabilization ofHSCs (n = 3).
pe).
d using a Student’s t test (D, H, I, J, K, N, and O) or an ANOVA followed by
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some of these proteasome targets within HSCs. Our RNA
sequencing data revealed a significant increase in the expres-
sion of cell cycle genes within Aarssti/sti HSCs (Figure 3B). In
accordance with these gene expression studies, we determined
that Aarssti/sti HSCs exhibited increased proliferation in vivo
compared to controls. After a 72-h pulse of bromodeoxyuridine
(BrdU) in vivo, 41.5% of Aarssti/sti HSCs incorporated BrdU
compared to 23.8% of control HSCs (Figure 3K; p < 0.05).
Because Aarssti/sti HSCs exhibited increased proliferation (Fig-
ure 3K) and diminished self-renewal activity (Figures 2N and 2O),
we sought to identify known proteasome-regulated targets that
could contribute to these phenotypes. The target that we
focused on was c-Myc. c-Myc has an established role in regu-
lating HSC quiescence, cell cycle entry, and self-renewal.
Although Myc is transcribed at similar levels in HSCs and pro-
genitors, the c-Myc protein is mostly absent from HSCs but ac-
cumulates in more differentiated progenitors (Reavie et al.,
2010). Conditional deletion of the E3 ubiquitin ligase Fbxw7 leads
to an accumulation of c-Myc protein within HSCs (Reavie et al.,
2010; Thompson et al., 2008), suggesting that Fbxw7 targets c-
Myc for degradation. Fbxw7/ HSCs exhibit increased cycling
and premature exhaustion (Matsuoka et al., 2008; Thompson
et al., 2008), which is similar to HSCs with enforced expression
of c-Myc (Wilson et al., 2004). Genetic inactivation of one allele
of Myc is sufficient to partially rescue Fbxw7/ HSCs (Reavie
et al., 2010). These studies indicate that proteasome-mediated
degradation of c-Myc is essential for normal HSC quiescence
and self-renewal.
Given that c-Myc is heavily regulated by the proteasome, pro-
motes HSC cell cycle entry, and influences HSC self-renewal, we
investigated whether c-Myc was dysregulated in Aarssti/sti mice.
We determined that Aarssti/sti HSCs/MPPs expressed elevated
amounts of c-Myc protein relative to controls (Figure 3L), but
no such changes were evident within restricted progenitors
(Figure 3M). The increase in the c-Myc protein could not be ex-
plained by increased Myc mRNA expression, which was un-
changed within Aarssti/sti HSCs (Figure 3N). Increased c-Myc
expression also could neither be explained by reduced expres-
sion of Fbxw7 nor any other E3 ubiquitin ligases implicated in
c-Myc ubiquitylation (Figures 3O and S4H–S4S). Although we
cannot rule out all possible mechanisms, our data suggest that
c-Myc accumulates within Aarssti/sti HSCs at least in part
because of impaired degradation as a consequence of over-
whelmed and/or impaired proteasome capacity.
To further support our findings in Aarssti/sti HSCs, we tested
whether an accumulation of misfolded and unfolded proteins
had similar effects on proteasome capacity and c-Myc expres-
sion in Pten-deficient HSCs that accumulate ubiquitylated
proteins as a consequence of increased protein synthesis (Fig-
ure 1O). Consistent with our observations in Aarssti/sti HSCs,
Pten-deficient HSCs exhibited a robust increase in c-Myc pro-
tein expression (Figure S4B) without any increase in Myc
mRNA expression (Figure S4C) or decline in Fbxw7 expression
(Figure S4D). In addition, we observed a significant increase in
GFP+ HSCs within Mx1-Cre+;Ptenfl/fl;UBG76V-GFP mice (Fig-
ure S4E), indicating that Pten-deficient HSCs also experience
an overwhelming or impairment of their proteasome without
any significant change in overall proteasome capacity (Fig-76 Cell Reports 30, 69–80, January 7, 2020ure S4F). Notably, the Rpl24Bst/+ mutation reduced the abun-
dance of c-Myc in Pten-deficient HSCs/MPPs to near wild-
type levels (Figure S4G). Taken together, these data strongly
suggest that amodest accumulation of misfolded proteins is suf-
ficient to overwhelm the capacity of the proteasomewithin HSCs
and is associated with accumulation of c-Myc.
Reducing c-Myc Expression Partially Rescues Self-
Renewal Defects in Aarssti/sti HSCs
Because c-Myc overexpression can impair HSC self-renewal,
we hypothesized that c-Myc accumulation within Aarssti/sti
HSCs was contributing to defects in serial reconstituting activ-
ity. To test this, we sought to reduce c-Myc expression within
Aarssti/sti HSCs. We could not completely delete Myc because
Myc deficiency causes severe hematopoietic defects (Wilson
et al., 2004). We, thus, sought to reduce c-Myc expression
by conditionally deleting a single allele of Myc in Aarssti/sti
mice by breeding Mx1-Cre+;Mycfl/+;Aarssti/sti (Aarssti/sti;Myc+/)
mice. Remarkably, c-Myc expression in Aarssti/sti HSCs was
reduced to near wild-type levels in Aarssti/sti;Myc+/ HSCs (Fig-
ure 4A), whereas levels of ubiquitylated protein were still
elevated (data not shown).
To test if reducing c-Myc expression could partially rescue
Aarssti/sti HSC self-renewal, we performed serial long-term
reconstitution assays. We competitively transplanted 5x105
Mx1-Cre+;Mycfl/+;Aarssti/sti, Aarssti/sti or wild-type control bone
marrow cells (CD45.2+) together with 5 3 105 congenic bone
marrow cells (CD45.1+) into lethally irradiated mice (CD45.1+)
(Figure 4B). Similar to our HSC transplants (Figure 2M), long-
term hematopoietic reconstitution from Aarssti/sti bone marrow
cells was statistically indistinguishable from controls in primary
recipients (Figure 4C). Aarssti/sti;Myc+/ bone marrow cells also
gave similar levels of reconstitution in primary transplants,
although they did exhibit a slight, but significant reduction in B
cell reconstitution. After 16 weeks, 3 3 106 bone marrow cells
from primary recipient mice were serially transplanted into
lethally irradiated mice. Secondary recipients of Aarssti/sti bone
marrow cells exhibited significantly less donor cell reconstitution
in all lineages after transplantation (Figure 4D). Strikingly,
reducing c-Myc expression in Aarssti/sti;Myc+/ HSCs partially
prevented these defects (Figure 4D). Aarssti/sti;Myc+/ cells
gave similar levels of reconstitution as wild-type cells, except
in the B cell lineage where reconstitution was still reduced (Fig-
ure 4D). Overall, long-termmultilineage reconstitution in second-
ary transplants was reduced from 95% (35/37) in recipients of
wild-type cells to 39% (17/44) in recipients of Aarssti/sti cells
(p < 0.001), but was increased back to 94% (16/17) in recipients
of Aarssti/sti;Myc+/ cells (Figure 4E; p < 0.001). These data indi-
cate that reducing c-Myc expression partially prevents self-
renewal defects within Aarssti/sti HSC, and suggest that c-Myc
accumulation contributes to impaired HSC function when pro-
teostasis is perturbed.
DISCUSSION
Low protein synthesis is a broadly conserved feature of so-
matic stem cells (Blanco et al., 2016; Llorens-Bobadilla et al.,
2015; Sanchez et al., 2016; Signer et al., 2014; Zismanov
Figure 4. Reducing c-Myc Expression Largely Rescues Serial Reconstituting Activity of Aarssti/sti HSCs
(A)Western blot examining c-Myc in 104 HSCs/MPPs isolated fromwild-type (+/+), Mx1-Cre+;Aarssti/sti;Mycfl/+ (sti/sti;Myc+/) andAarssti/sti (sti/sti;Myc+/+) mice.
(B) Diagram showing bone marrow transplantation strategy.
(C) Donor cell engraftment 16weeks after 53 105 bonemarrow cells fromwild-type (+/+),Aarssti/sti (sti/sti;Myc+/+) andMx1-Cre+;Aarssti/sti;Mycfl/+ (sti/sti;Myc+/)
mice were transplanted with 53 105 recipient-type bonemarrow cells into irradiated mice. Total hematopoietic cells, B cell, T cell, andmyeloid cell engraftment is
shown (n = 4–8 donors and 26–44 total recipients/genotype).
(D) Donor cell engraftment in secondary recipients (n = 4–10 donors and 17–44 recipients/genotype).
(E) Frequency of secondary recipients in (D) that exhibited long-term multilineage reconstitution.
Data represent mean ± standard error of the mean. Statistical significance was assessed using a Student’s t test (C and D) or Fisher’s exact test (E). *p < 0.05;
**p < 0.01; ***p < 0.001.et al., 2016) that promotes regeneration in multiple tissues.
However, little is known about why stem cells depend upon
low protein synthesis and why modest increases in protein syn-
thesis impair stem cell function. In this study, we set out to
address this question by examining the influence of protein
synthesis on protein quality and homeostasis. We found that
HSCs contain less ubiquitylated and unfolded protein than
restricted myeloid progenitors in vivo (Figure 1) and that
modest increases in protein synthesis reduce protein quality
within HSCs. To investigate the consequences of reduced pro-
tein quality on HSCs independent of changes in protein synthe-
sis rate, we examined Aarssti/sti mice that have a defect in tRNA
editing activity. The accumulation of defective translational
products within Aarssti/sti HSCs impaired their serial long-term
multilineage reconstituting activity (Figure 2). Surprisingly, we
found that the accumulation of misfolded proteins over-
whelmed and/or impaired the proteasome and led to increased
c-Myc abundance in both Aarssti/sti and Pten-deficient HSCs
(Figures 3 and S4). Reducing c-Myc expression by deleting asingle allele of Myc partially prevented the self-renewal defects
observed in Aarssti/sti HSCs (Figure 4). Overall, our studies indi-
cate that stem cells depend upon low protein synthesis to
maintain proteome quality and that modest accumulation of
misfolded proteins preferentially impairs HSC self-renewal.
Our finding that the proteasome gets overloaded and impaired
in HSCs raises the possibility that stem cells may depend on
alternative mechanisms to detoxify and eliminate misfolded pro-
teins. One possibility is that HSCs preferentially depend upon
autophagy to degrademisfolded proteins. In support of this pos-
sibility, two recent studies reported that autophagy promotes
proteostasis maintenance within aging neural stem cells (Lee-
man et al., 2018) and muscle satellite cells (Garcı´a-Prat et al.,
2016). Similar to HSCs, quiescent neural stem cells also contain
less proteasome activity than restricted progenitors and neural
stem cells preferentially store misfolded proteins as aggregates
in lysosomes (Leeman et al., 2018). Several studies have demon-
strated an essential role for autophagy in HSCs (Ho et al., 2017;
Liu et al., 2010; Mortensen et al., 2011; Warr et al., 2013), but toCell Reports 30, 69–80, January 7, 2020 77
our knowledge, whether autophagy promotes proteostasis
maintenance within HSCs is unstudied.
In addition to degradation pathways, HSCs could eliminate
misfolded proteins through proliferation. Cell division enables
cells to dilute out misfolded proteins by distributing them to
daughter cells. We determined that a buildup of misfolded pro-
teins led to an accumulation of c-Myc and increased prolifera-
tion in HSCs but not restricted progenitors (Figure 3). These
data reveal a stem-cell-specific molecular mechanism connect-
ing the proteostasis network to cell cycle control. An intriguing
possibility is that HSCs sense changes in protein synthesis and
homeostasis by proteasome-mediated turnover of c-Myc, and
c-Myc accumulation could be an adaptive mechanism used
by individual HSCs to restore proteostasis within daughter
stem cells generated by self-renewing divisions. Furthermore,
this mechanism could also protect the HSC pool because
HSCs unable to restore proteostasis would have sustained
c-Myc expression, which promotes HSC differentiation (Wilson
et al., 2004).
c-Myc is not the only protein in HSCs whose expression is
regulated by the proteasome (Moran-Crusio et al., 2012). Inter-
estingly, a previous report determined that expression of p53,
which is also heavily regulated by the proteasome in HSCs (Ab-
bas et al., 2010), is elevated within Pten-deficient HSCs and con-
tributes to self-renewal defects in that background (Lee et al.,
2010). Deleting a single allele of Myc also modestly restores
long-term multilineage, reconstituting activity within Pten-defi-
cient HSCs (data not shown). Overwhelming of the proteasome
due to an accumulation of misfolded and unfolded proteins is
likely to have more widespread effects on HSC proteome con-
tent. However, detailed proteomic analyses needed to broadly
investigate this possibility remain technically difficult to perform
within rare HSCs.
Disrupted proteostasis is a hallmark of aging (Lo´pez-Otı´n
et al., 2013), but whether it contributes to HSC aging is still un-
tested. An intriguing possibility is that disrupted proteostasis in
aging HSCs could contribute to HSC dysfunction and the
increased incidence of blood cancer in the elderly by preventing
the degradation of c-Myc. A potential role for c-Myc in stem cell
aging could extend a recent study that demonstrated that
reducing Myc expression enhances longevity in mice (Hofmann
et al., 2015).
Low protein synthesis is a shared feature of many types of so-
matic stem cells (Blanco et al., 2016; Llorens-Bobadilla et al.,
2015; Sanchez et al., 2016; Signer et al., 2014; Zismanov et al.,
2016). Our findings raise the possibility that the maintenance of
proteostasis is similarly required by stem cells in diverse tissues.
Interestingly, interventions that reduce protein synthesis and
enhance proteostasis extend organismal lifespan in an evolu-
tionarily conserved manner (Taylor and Dillin, 2011). Our current
findings suggest that mechanisms that promote organismal
longevity are conserved at the cellular level tomaintain long-lived
stem cells in vivo.
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Antibodies
APC Anti-mouse CD3ε (17A2) BioLegend Cat #100236
FITC Anti-mouse CD3ε (17A2) BioLegend Cat #100204
PE Anti-mouse CD3ε (17A2) BioLegend Cat #100206
APC Anti-mouse CD4 (GK1.5) BioLegend Cat #100412
FITC Anti-mouse CD4 (GK1.5) BioLegend Cat #100406
PE Anti-mouse CD4 (GK1.5) BioLegend Cat #100408
APC Anti-mouse CD5 (53-7.3) BioLegend Cat #100626
FITC Anti-mouse CD5 (53-7.3) BioLegend Cat #100606
PE Anti-mouse CD5 (53-7.3) BioLegend Cat #100608
APC Anti-mouse CD8a (53-6.7) eBioscience Cat #17-0081-82
FITC Anti-mouse CD8a (53-6.7) eBioscience Cat #11-0081-85
PE Anti-mouse CD8a (53-6.7) eBioscience Cat #12-0081-83
APC Anti-mouse CD11b (M1/70) eBioscience Cat #17-0112-82
APC efluor780 Anti-mouse CD11b (M1/70) eBioscience Cat #47-0112-82
FITC Anti-mouse CD11b (M1/70) eBioscience Cat #12-0112-83
PE Anti-mouse CD11b (M1/70) eBioscience Cat #11-0112-85
PE/Cy7 Anti-mouse CD16/32 (FcgRII/III; 93) BioLegend Cat #101318
PerCP/Cy5.5 Anti-mouse CD16/32 (FcgRII/III; 93) BioLegend Cat #101324
Biotin Anti-mouse CD34 (RAM34) eBioscience Cat #13-0341-85\
eFluor660 Anti-mouse CD34 (RAM34) eBioscience Cat #50-0341-82
Alexa Fluor 700 Anti-mouse CD34 (RAM34) eBioscience Cat #56-0341-82
FITC Anti-mouse CD34 (RAM34) eBioscience Cat #11-0341-85
FITC Anti-mouse CD43 (R2/60) eBioscience Cat #11-0431-85
PE Anti-mouse CD43 (R2/60) eBioscience Cat #12-0431-83
APC eFluor 780 Anti-mouse CD45.1 (A20) eBioscience Cat #47-0453-82
Alexa Fluor 700 Anti-mouse CD45.2 (104) BioLegend Cat #109822
FITC Anti-mouse CD45.2 (104) BioLegend Cat #109806
APC Anti-mouse CD45R (B220) (RA3-6B2) eBioscience Cat #17-0452-83
FITC Anti-mouse CD45R (B220) (RA3-6B2) eBioscience Cat #11-0452-85
PE Anti-mouse CD45R (B220) (RA3-6B2) eBioscience Cat #12-0452-85
PerCP-Cyanine5 Anti-mouse CD45R (B220) (RA3-6B2) eBioscience Cat #45-0452-82
APC Anti-mouse CD48 (HM48-1) BioLegend Cat #103412
FITC Anti-mouse CD48 (HM48-1) BioLegend Cat #103404
PE Anti-mouse CD48 (HM48-1) BioLegend Cat #103406
PE/Cy7 Anti-mouse CD48 (HM48-1) BioLegend Cat #103424
FITC Anti-mouse CD71 (R17217) eBioscience Cat #11-0711-85
APC Anti-mouse CD117 (cKit) (2B8) eBioscience Cat #17-1171-83
APC eFluor 780 Anti-mouse CD117 (cKit) (2B8) eBioscience Cat #47-1711-82
PE-Cyanine7 Anti-mouse CD117 (cKit) (2B8) eBioscience Cat #25-1711-82
PE Anti-mouse CD127 (IL7Ra; A7R34) BioLegend Cat #135010
APC Anti-mouse CD150 (TC15-12F12.2) BioLegend Cat #115910
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PE Anti-mouse CD150 (TC15-12F12.2) BioLegend Cat #115904
PE-Cyanine7 Anti-mouse CD150 (TC15-12F12.2) BioLegend Cat #115914
APC Anti-mouse Ter119 (TER-119) Biolegend Cat #116212
FITC Anti-mouse Ter119 (TER-119) Biolegend Cat #116206
PE Ter119 (TER-119) Biolegend Cat #116208
APC Anti-mouse Sca-1 (D7, E13-161.7)\ eBioscience Cat #17-5981-82
Alexa Fluor 700 Anti-mouse Sca-1 (D7, E13-161.7) eBioscience Cat #56-5981-82
FITC Anti-mouse Sca-1 (D7, E13-161.7) eBioscience Cat #11-5981-85
PerCp-Cyanine5.5 Anti-mouse Sca-1 (D7, E13-161.7) eBioscience Cat #45-5981-82
APC Anti-mouse Gr-1 (RB6-8C5) BioLegend Cat #108412
FITC Anti-mouse Gr-1 (RB6-8C5) BioLegend Cat #108406
PE Anti-mouse Gr-1 (RB6-8C5) BioLegend Cat #108408
PE/Cy7 Anti-mouse Gr-1 (RB6-8C5) BioLegend Cat #108416
APC Anti-mouse IgM (II/41) eBioscience Cat #17-5790-82
PE Anti-mouse IgM (II/41) eBioscience Cat #12-5790-83
Streptavidin-PECy7 BioLegend Cat #405206
Anti-Ubiquitin (P4D1) Cell Signaling Cat #3933S
Anti-K48-Polyubiquitin (polyclonal) Cell Signaling Cat# 4289S
Anti-c-Myc (polyclonal) Cell Signaling Cat# 9402S
Anti-phos-Eif2a (S51) Cell Signaling Cat #9721S
Anti-b-Actin (AC74) Sigma Cat #A2228
Anti-Gapdh (14C10) Cell Signaling Cat #2118S
HRP-linked anti-rabbit IgG Cell Signaling Cat #7074S
HRP-linked anti-mouse IgG Cell Signaling Cat #7076S
Chemicals, Peptides, and Recombinant Proteins
PIPC GE Healthcare
Biosciences Corp
Cat #27473201
Anti-mouse CD117 microbeads Miltenyi Cat #130-091-224
TCA Sigma Cat #T6399
Triton X-100 CalBiochem Cat #648466
LDS loading buffer Life Technologies Cat #NP007
SDS Life Technologies Cat #NP0060
Glycine Sigma Cat #50046
Tetraphenylethene maleimide (TMI) Dr. Yuning Hong Custom Synthesized
OP-Puro Medchem Source Custom Synthesized
SYPRO Ruby Protein Gel Stain Bio-Rad Cat #1703125
2-mercaptoethanol Sigma Cat #M3148
SYBR green Roche Cat #4707516001
Critical Commercial Assays
SuperSignal West Femto or Pico PLUS
chemiluminescence kit
Thermo Scientific Cat #34095
Click-iT Cell Reaction Buffer Kit Life Technologies Cat #C10269
Alexa Fluor 555-conjugated azide Life Technologies Cat #A20012
Proteasome-Glo chymotrypsin-like cell based assay Promega Cat #G8660
RNeasy Plus Micro Kit QIAGEN Cat #74034
RT2 First Strand Kit QIAGEN Cat #330404
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Deposited Data
RNA-sequencing data (Aarssti/sti and Aars+/+ HSCs) GEO GSE141008
Experimental Models: Organisms/Strains
Mouse: B6: C57BL/6J The Jackson Laboratory Cat #000664
Mouse: B6SJL: B6.SJL The Jackson Laboratory Cat #002014
Mouse: Ptenfl/fl The Jackson Laboratory Cat #006440
Mouse: Mx1-Cre The Jackson Laboratory Cat #003556
Mouse: Rpl24Bst/+ The Jackson Laboratory Cat #000516
Mouse: Aarssti/sti The Jackson Laboratory Cat #002560
Mouse: UbG76V-GFP The Jackson Laboratory Cat #008111
Mouse: Mycfl The Jackson Laboratory Cat #011123
Oligonucleotides
Myc forward IDT 50- CTTCTCTCCTTCCTCGGACTC-30
Myc reverse IDT 50- GGAGATGAGCCCGACTCCGACCTC-30
b-Actin forward IDT 50-CGTCGACAACGGCTCCGGCATG-30
b-Actin reverse IDT 50-GGGCCTCGTCACCCACATAGGAG-30
Software and Algorithms
FlowJo FlowJo, LLC N/A
FACSDiva BD Bioscience N/A
Prism 8 GraphPad N/A
ImageJ NIH N/A
Image Lab 6.0.1 Bio-Rad N/A
TopHat 1.4.1 JHU CCB N/A
PRINSEQ Lite 0.20.3 N/A N/A
Htseq-count 0.7.1 N/A N/A
Bioconductor package DESeq2 1.6.3 Bioconductor N/ALEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead
Contact, Dr. Robert Signer (rsigner@ucsd.edu). TMI was synthesized by Dr. Yuning Hong and is available from her upon request
(Y.Hong@latrobe.edu.au).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
C57BL/6J, C57BL6.SJL, Ptenfl/fl, Mx1-Cre, Rpl24Bst/+, Aarssti/sti, UbG76V-GFP, and Mycfl mice were housed in pathogen-free
conditions.
Ptenfl/fl (Groszer et al., 2006), and Mycfl mice (de Alboran et al., 2001) were bred to Mx1-Cre (Cre+) (K€uhn et al., 1995) mice to
generate Mx1-Cre+;Ptenfl/fl and Mx1-Cre+;Mycfl mice, respectively. Mx1-Cre+;Ptenfl/fl mice were further crossed to Rpl24Bst/+ mice
(Oliver et al., 2004) to yield Mx1-Cre+;Ptenfl/fl;Rpl24Bst/+ mice. Aarssti/sti mice (Lee et al., 2006) were bred to Mx1-Cre+;Mycfl mice to
produce Mx1-Cre+;Mycfl/+;Aarssti/sti mice. Mx1-Cre+;Ptenfl/fl and Aarssti/sti were bred to UbG76V-GFP mice (Lindsten et al., 2003) to
generate Mx1-Cre+;Ptenfl/fl;UBG76V-GFP and UbG76V-GFP;Aarssti/sti mice, respectively. Mutant mice were all backcrossed for at
least ten generations onto a C57BL background. C57BL6/J (CD45.2) and C57BL6.SJL (CD45.1) mice were used in transplantation
experiments.
Both male and female mice between 6 and 12 weeks of age were used in these studies. All mice were housed in the vivarium at the
UC San Diego Moores Cancer Center. All protocols were approved by the UC San Diego Institutional Animal Care and Use
Committee.Cell Reports 30, 69–80.e1–e6, January 7, 2020 e3
Cell isolation
Bone marrow cells were isolated by flushing the long bones (femurs and tibias) or by crushing the long bones, vertebrae and pelvic
bones with a mortar and pestle in Ca2+- and Mg2+-free Hank’s buffered salt solution (HBSS; Corning) supplemented with 2% (v/v)
heat-inactivated bovine serum (GIBCO). Spleens were prepared by crushing tissues between frosted slides. All cells were filtered
through a 40 mmcell strainer to obtain single cell suspensions. Cell number and viability were assessed with a hemocytometer based
on trypan blue exclusion.
METHOD DETAILS
PIPC treatment
Expression of Mx1-Cre was induced by three or four intraperitoneal injections of 10 mg polyinosinic-polycytidylic acid (pIpC;
GE Healthcare) administered every other day, beginning at approximately 6 weeks of age.
Proteasome inhibition
For proteasome inhibition experiments, mice were administered bortezomib (Cell Signaling; 1 mg/kg) diluted in 10% (v/v) DMSO via
retro-orbital injection.
Flow cytometry and sorting
For flow cytometric analysis and isolation of specific hematopoietic progenitors, cells were incubated with combinations of anti-
bodies to the following cell-surface markers, conjugated to FITC, PE, PerCP-Cy5.5, APC, PE-Cy7, eFluor 660, Alexa Fluor 700,
APC-eFluor 780 or biotin (antibody clones are given in brackets in the following list): CD3ε (17A2), CD4 (GK1.5), CD5 (53-7.3),
CD8a (53-6.7), CD11b (M1/70), CD16/32 (FcgRII/III; 93), CD34 (RAM34), CD43 (R2/60), CD45.1 (A20), CD45.2 (104), CD45R
(B220; RA3-6B2), CD48 (HM48-1), CD71 (R17217), CD117 (cKit; 2B8), CD127 (IL7Ra; A7R34), CD150 (TC15-12F12.2), Ter119
(TER-119), Sca-1 (D7, E13-161.7), Gr-1 (RB6-8C5) and IgM (II/41). For isolation of HSCs and MPPs, Lineage markers included
CD3, CD5, CD8, B220, Gr-1 and Ter119. For isolation of CMPs, GMPs and MEPs, these Lineage markers were supplemented
with additional antibodies against CD4 and CD11b. Biotinylated antibodies were visualized by incubation with PE-Cy7 conjugated
streptavidin. All reagents were acquired from eBiosciences, or BioLegend. All incubations were for 30-90 min on ice.
HSCs, MPPs, CD34+CD16/32lowCD127-Lineage-Sca-1-c-kit+ CMPs (Akashi et al., 2000), CD34+CD16/32highCD127-Lineage-Sca-
1-c-kit+ GMPs (Akashi et al., 2000), and CD34-CD16/32-/lowCD127-Lineage-Sca-1-c-kit+ MEPs (Akashi et al., 2000) were pre-en-
riched by selecting c-kit+ cells using paramagnetic microbeads and an autoMACS magnetic separator (Miltenyi Biotec) before
sorting.
Non-viable cells were excluded from sorts and analyses using 4’,6-diamidino-2-phenylindole (DAPI). Apoptotic cells were identi-
fied using APC annexin V (BDBiosciences). Proliferation was assessed by administering 5-bromo-20-deoxyuridine (BrdU; Sigma) to
mice. BrdU dissolved in PBSwas administered with an initial intraperitoneal injection (2 mg) and thenmice were maintained on drink-
ing water containing 1 mg/ml BrdU for 72 h. BrdU incorporation in HSCs was measured using the APC BrdU Flow Kit (BD
Biosciences).
For analysis of ubiquitylated protein following cell surface staining, cells were fixed in 0.5 mL of 1% paraformaldehyde (Affymetrix)
in PBS for 10-15 min on ice. Cells were washed in PBS, then permeabilized in 200 mL PBS supplemented with 3% (v/v) fetal bovine
serum (Life Technologies) and 0.1% (m/v) saponin (Sigma) for 5 min at room temperature (20–25C). Cells were then incubated with
anti-ubiquitylated protein antibody (clone FK2, Millipore) at a concentration of 1:500 for 30 min at room temperature. This was fol-
lowed by incubation with anti-mouse Alexa Fluor 488 (Thermo Scientific) at a concentration of 1:500 for 30 min at room temperature.
Cells were washed twice in PBS supplemented with 3% fetal bovine serum and 0.1% saponin, then resuspended in PBS supple-
mented with DAPI (4 mg/ml final concentration) and analyzed by flow cytometry.
Data acquisition and cell sorting were performed on a FACSAria II, LSR II or FACSCanto flow cytometer (BD Biosciences). Sorted
fractions were typically double sorted to ensure high purity. Data were analyzed by FlowJo (TreeStar) software.
Competitive repopulation assay
Adult recipient mice (CD45.1) were administered a minimum lethal dose of radiation using a Mark I Cesium source irradiator
(J.L. Sheperd) to deliver two doses of 550 rad (1,100 rad in total) at least 4 h apart. Cells were injected into the retro-orbital venous
sinus of anaesthetized recipients. For competitive bone marrow transplants 5x105 donor and 5x105 recipient-type cells were trans-
planted. For HSC transplants 10 donor CD150+CD48-Lineage-Sca-1+c-kit+ HSCs and 2x105 recipient-type bone marrow cells were
transplanted. Blood was obtained from the tail veins of recipient mice every 4 weeks for at least 16 weeks after transplantation. Red
blood cells were lysed with ammonium chloride potassium buffer. The remaining cells were stained with antibodies against CD45.2,
CD45.1, CD45R (B220), CD11b, CD3 and Gr-1 to assess donor-cell engraftment.
For secondary transplants, 3x106 bone marrow cells collected from primary recipients were transplanted non-competitively into
irradiated recipient mice. Primary recipients used for secondary transplantation had long-term multilineage reconstitution by donor
cells and median levels of donor-cell reconstitution for the treatments from which they originated. Mice that died over the course of
transplantation experiments were omitted from the analyses.e4 Cell Reports 30, 69–80.e1–e6, January 7, 2020
ForMPP transplants, 50 CD150-CD48-Lineage-Sca-1+c-kit+MPPs and 2x105 recipient-type bonemarrow cells were transplanted.
Blood was obtained from the tail veins of recipient mice 3,5 and 7 weeks after transplantation.
Western blot analysis
Equal numbers of cells from each stem or progenitor population were sorted into trichloracetic acid (TCA, Sigma). The final concen-
trationwas adjusted to 10% (v/v) TCA. Extracts were incubated on ice for at least 15min and centrifuged at 15,000 g at 4C for 15min.
Precipitates were washed in acetone twice and dried. The pellets were solubilized in 9 M urea, 2% (v/v) Triton X-100, and 1% DTT.
LDS loading buffer (Life Technologies) was added and the pellet was heated at 70C for 10 min. Samples were separated on Bis-
Trispolyacrylamide gels (Life Technologies) and transferred to PVDF membranes (Bio-Rad). Western blot analyses were performed
according to the protocol from Cell Signaling Technologies. Blots were stripped with 1% SDS, 25 mM glycine (pH 2) before re-prob-
ing. The following primary and secondary antibodies were used for western blot analyses: Ubiquitin (P4D1; Cell Signaling), K48-Ubiq-
uitin (polyclonal; Cell Signaling 4289), c-Myc (polyclonal; Cell Signaling 9402S), phos-Eif2a (S51; Cell Signaling) b-Actin (AC74;
Sigma), Gapdh (14C10; Cell Signaling), HRP-linked anti-rabbit IgG (Cell Signaling) and HRP-linked anti-mouse IgG (Cell Signaling).
Blots were developed with the SuperSignal West Femto or Pico PLUS chemiluminescence kit (Thermo Scientific).
Measurement of unfolded proteins
4x106 bone marrow cells were stained for cell surface markers as described above. After staining, cells were washed twice in
Ca2+- and Mg2+-free PBS. Tetraphenylethene maleimide (TMI; stock 2 mM in DMSO) was diluted in PBS (50 mM final concentra-
tion), added to each sample and samples were incubated at 37C for 45 minutes. Samples were washed twice in PBS and
analyzed by flow cytometry. DAPI was omitted from these samples because of spectral overlap.
To assess the effects of heat shock, 106 BM cells were incubated Ca2+- and Mg2+-free HBSS (Corning) supplemented with 2%
heat-inactivated bovine serum at 37C or 42C for 4 h. Cells were then washed twice in Ca2+- and Mg2+-free PBS (Corning), and
TMI was added as described above.
In vivo measurement of protein synthesis
OP-Puro (Medchem Source; 50 mgkg-1 body mass; pH 6.4–6.6 in PBS) was injected intraperitoneally. One hour later mice were
euthanized. Bone marrow was collected, and 4x106 cells were stained with combinations of antibodies against cell-surface markers
as described above. After washing, cells were fixed in 0.5 mL of 1% paraformaldehyde (Affymetrix) in PBS for 10-15min on ice. Cells
werewashed in PBS, then permeabilized in 200mLPBS supplementedwith 3% (v/v) fetal bovine serum (Life Technologies) and 0.1%
(m/v) saponin (Sigma) for 5min at room temperature (20–25C). The azide-alkyne cycloaddition was performed using the Click-iT Cell
Reaction Buffer Kit (Life Technologies) and azide conjugated to Alexa Fluor 555 (Life Technologies) at 5 mM final concentration. After
the 30-min reaction, the cells were washed twice in PBS supplemented with 3% fetal bovine serum and 0.1% saponin, then resus-
pended in PBS supplementedwith DAPI (4mgml-1 final concentration) and analyzed by flow cytometry (Hidalgo San Jose and Signer,
2019).
In vitro analysis
Colony forming units were assessed by sorting 500 live bone marrow cells per well of a 96-well plate (24 wells per mouse) containing
methylcellulose culture medium (M3434; STEMCELL Technologies). Colonies were counted after 14 days.
Cell volume
Average diameter was measured by sorting cells into flat-bottom 96-well plates and analyzing micrographs with ImageJ software.
Cell volume was calculated based on the assumption that cells are spherical (4/3*p*r3).
Protein content
Equal numbers of cells from each stem or progenitor population were sorted into HBSS supplemented with 2% (v/v) heat-inacti-
vated bovine serum (GIBCO). Samples were washed once with PBS and centrifuged at 2500 g at 4C for 5 min. Supernatant was
discarded and protein pellets were directly lysed and solubilized in 9M urea, 2% SDS, 50 mM DTT, and 50 mM Tris pH 7.4. After
incubating the samples for 10-15 min at room temperature, LDS loading buffer (Life Technologies) was added and the sample was
heated at 70C for 10 minutes. Samples were separated on Bis-Trispolyacrylamide gels (Life Technologies). The Bis-Trispolyacry-
lamide gels were then stained with SYPRO Ruby Protein Gel Stain (Bio-Rad) for 3 h and washed in a solution containing 7% acetic
acid and 10% methanol for 1 h. Gels were imaged using Gel Doc XR (Bio-Rad) and analyzed with Image Lab 6.0.1 software (Bio-
Rad).
For bone marrow cells, incubated at 37C or 42C, 105 cells were sorted into TCA. The final concentration was adjusted to 10%
TCA. Extracts were incubated on ice for at least 15 min and centrifuged at 15,000 g at 4C for 15 min. Precipitates were washed in
acetone twice and dried. The pellets were solubilized in 6M urea, 2% (v/v) Triton X-100, and 1% (v/v) 2-mercaptoethanol. The protein
content in the supernatant was assessed with the microBCA assay (Pierce).Cell Reports 30, 69–80.e1–e6, January 7, 2020 e5
Proteasome activity
5x103 cells from each cell population were plated into 96-well plates in triplicate. Proteasome activity was measured with the Pro-
teasome-Glo chymotrypsin-like cell based assay (Promega). Luminescence wasmonitored after a 15min incubation using a Synergy
HTX multi-mode plate reader. HSCs/MPPs incubated with 100 mM MG132 were used as controls.
RNA sequencing
For RNA-seq analysis, total RNAwas extracted from3000HSCs using the RNeasy PlusMicro Kit (QIAGEN). IlluminamRNA libraries
were prepared using the SMARTseq2 protocol (Picelli et al., 2014). 2.6 mL of total RNAwas used in the SMARTSeq2 protocol (70pg to
1.62ng). 18 cycles of PCR were performed for the cDNA preamplification step and 12 cycles were performed for the tagmentation
library preparation. The resulting libraries were pooled and deep sequenced in two lanes on the Illumina HiSeq 2500 in high output
mode using single-end reads with lengths of 50 nucleotides (25-35M reads per condition). The single-end reads that passed Illumina
filters were filtered for reads aligning to tRNA, rRNA, adaptor sequences, and spike-in controls. The reads were then aligned to the
mm10 reference genome using TopHat (v 1.4.1) (Trapnell et al., 2009). DUST scores were calculated with PRINSEQ Lite (v 0.20.3)
(Schmieder and Edwards, 2011) and low-complexity reads (DUST > 4) were removed from the BAM files. The alignment results
were parsed via the SAMtools (Li et al., 2009) to generate SAM files. Read counts to each genomic feature were obtained with
the htseq-count program (v 0.7.1) (Anders et al., 2015) using the ‘‘union’’ option. After removing absent features (zero counts in all
samples), the raw counts were then imported to Bioconductor package DESeq2 (v 1.6.3) (Love et al., 2014) to identify differentially
expressed genes among samples. P values for differential expression are calculated using the Wald test for differences between the
base means of two conditions. These P values are then adjusted for multiple test correction using Benjamini Hochberg algorithm.We
considered genes differentially expressed between two groups of samples when the DESeq2 analysis resulted in an adjusted P value
of < 0.10 and the difference in gene expression was at least 2-fold. Principal Component Analysis (PCA) was performed using the
‘prcomp’ function in R. Heatmaps of differentially expressed genes were generated from log2(RPKM+1) values using the function
heatmap.2(package gplots) in R. GSEA with classic scoring scheme was run for the geneset Biological processes (c5.bp.v6.1.sym-
bols.gmt) from MSigDB on pre-ranked gene lists. For genes with log2FoldChange greater than zero, a rank -log10(pValue) was as-
signed and for genes with log2FoldChange less than zero, a rank of log10(pValue) was assigned.
Quantitative PCR
Cells were sorted directly into RLT plus buffer (QIAGEN) supplemented with 2-mercaptoethanol. RNAwas extracted with the RNeasy
micro plus kit (QIAGEN) and cDNAwas synthesized with the RT2 First Strand Kit (QIAGEN). Reactions were run in 20 mL volumes with
SYBR green and a LightCycler 480 (Roche Applied Science). Primer sequences were:Myc F, 50- CTTCTCTCCTTCCTCGGACTC-30;
Myc R 50- GGAGATGAGCCCGACTCCGACCTC-30; b-Actin F, 50-CGTCGACAACGGCTCCGGCATG-30; b-Actin R, 50-GGGCC
TCGTCACCCACATAGGAG-30
QUANTIFICATION AND STATISTICAL ANALYSIS
Group data are represented by mean ± standard deviation, except for transplantation data which are represented as mean ± stan-
dard error of the mean. To test statistical significance between two samples, two-tailed Student’s t tests were used. When multiple
samples were compared, statistical significance was assessed using a one-way ANOVA or a repeated-measures one-way ANOVA
(when comparingmultiple time points or populations from the samemouse) followed by Dunnett’s test for multiple comparisons. Sta-
tistical significance comparing overall numbers of mice with long-term multilineage reconstitution was assessed by a Fisher’s exact
test. Statistical tests were performed usingGraphPad Prism software. The specific type of test used for each figure panel is described
in the figure legends, except for the RNA sequencing data which is described in the ‘‘RNA sequencing’’ paragraph of the STAR
Methods section above.
For normalized data, means were calculated and statistical tests were performed using log10-transformed data and then means
were back-transformed to prevent data skewing. No randomization or blinding was used in any experiments. The only mice excluded
from any experiment were those that died after transplantation.
DATA AND CODE AVAILABILITY
The RNA-sequencing data comparing Aarssti/sti and control HSCs is available at Gene Expression Omnibus: GSE141008.e6 Cell Reports 30, 69–80.e1–e6, January 7, 2020
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Figure S1. Quantifying unfolded protein abundance within hematopoietic stem and progenitor cells with 
TMI. Related to Figure 1. 
(A) Western blot examining LysK48-ubiquitylated protein in 104 HSCs/MPPs, CMPs, GMPs and MEPs (one of two 
representative blots). (B) Representative histogram showing TMI fluorescence in bone marrow cells after a 4 h 
incubation at 37°C or 42°C. (C) Representative histogram showing TMI fluorescence in bone marrow cells from 
mice treated 18 h earlier with bortezomib (BZ) or vehicle (DMSO). (D) Western blot analysis showing ubiquitylated 
protein in 3x104 unfractionated bone marrow cells, as well as bone marrow cells with low (lowest quartile, bottom 
25%) and high (highest quartile, top 25%) of TMI fluorescence. (E) Representative flow cytometry plots showing 
gating strategies for analysis and isolation of HSCs and MPPs. (F) Representative histograms showing TMI 
fluorescence in HSCs. The background from PBS treated controls is shown in gray. (G) Representative flow 
cytometry plots showing gating strategies for analysis and isolation of CMPs, GMPs and MEPs. (H-J) 
Representative histograms showing TMI fluorescence in CMPs (H), GMPs (I) and MEPs (J). The background from 
PBS treated controls is shown in gray. (K) TMI fluorescence relative to total protein content in HSCs, CMPs, GMPs 
and MEPs (data from Fig. 1F,L). Data in K represent mean ± standard deviation. Statistical significance was 
assessed using an ANOVA followed by Dunnett’s multiple comparisons test relative to HSCs. ***P<0.001. 
 
 
Figure S2. Aarssti/sti mice have normal frequencies of lymphoid, myeloid and erythroid lineage cells. Related to 
Figure 2. 
(A) Cell volume of wild-type (+/+) and Aarssti/sti (sti/sti) HSCs (n ≥ 78 cells/population). (B-P) Frequency of IgM-
CD45R(B220)+CD43+ pro-B cells (Hardy et al., 1991), IgM-CD45R(B220)+CD43- pre-B cells (Hardy et al., 1991), 
IgM+CD45R(B220)+ B cells (D, L), CD4+CD8- T cells, (E, M) CD4-CD8+ T cells, (F, N) CD71+Ter119+ erythroid 
cells (Zhang et al., 2003) and CD11b+Gr1+ myeloid cells (H, P)  in the bone marrow (B-H) and spleen (J-P) of wild-
type (+/+) and Aarssti/sti mice (n = 6 mice per genotype). (I) Spleen (SPL) cellularity in wild-type (+/+) and Aarssti/sti 
(sti/sti) mice (n = 6 mice per genotype). Data represent mean ± standard deviation. Statistical significance was 
assessed using a two-tailed Student’s t-test. **P<0.01. 
 
  
 
 
Figure S3. Aarssti/sti MPPs have normal capacity to reconstitute irradiated mice in short-term transplantation. 
Related to Figure 2. (A-D) Flow cytometry analysis showing relative ubiquitylated protein content in Aarssti/sti 
(sti/sti) relative to wild-type (+/+) CMPs (A), GMPs (B), MEPs (C) and MPPs (D) (n = 4 mice per genotype). (E) 
Frequency of MPPs in the bone marrow of wild-type (+/+) and Aarssti/sti mice (n = 6 mice per genotype). (F) 
Diagram showing MPP transplantation strategy. (G) Donor cell engraftment when 50 CD150-CD48-LSK MPPs 
from wild-type (+/+) and Aarssti/sti (sti/sti) mice were transplanted along with 2x105 recipient bone marrow cells into 
irradiated mice (n = 3 donors and 15 recipients per genotype). Data represent mean ± standard deviation (A-E) or 
standard error of the mean (G). Statistical significance was assessed using a two-tailed Student’s t-test. *P<0.05. 
 
 
 
 
Figure S4. Accumulation of ubiquitylated protein overwhelms the proteasome leading to c-Myc stabilization 
in HSCs. Related to Figure 3. 
(A) Gene set enrichment analysis demonstrating no significant activation of the UPRER in Ptenfl/fl (Pten+/+) as 
compared to Mx1-Cre+;Ptenfl/fl (Pten-/-) HSCs. (B) Western blot examining c-Myc protein in 104 HSCs/MPPs 
isolated from Ptenfl/fl (+/+) and Mx1-Cre+;Ptenfl/fl (Pten-/-) mice (one of three representative blots). (C) Myc mRNA 
expression normalized to b-Actin in Ptenfl/fl (+/+) and Mx1-Cre+;Ptenfl/fl (Pten-/-) HSCs (n = 3 per genotype). (D) 
Fbxw7 expression in Ptenfl/fl (+/+) and Mx1-Cre+;Ptenfl/fl (Pten-/-) HSCs (n = 3 per genotype). (E) Frequency of 
HSCs that are GFP+ in the bone marrow of UbG76V-GFP (+/+) and Mx1-Cre+;UbG76V-GFP;Ptenfl/fl (Pten-/-) mice (n 
= 4-5 mice per genotype). (F) Relative proteasome activity in Ptenfl/fl (+/+) and Mx1-Cre+;Ptenfl/fl (Pten-/-) HSCs 
HSCs/MPPs (n = 9 replicates per genotype in 3 experiments). (G) Western blot examining ubiquitylated protein in 
3x104 wild-type (Ptenfl/fl;Rpl24+/+), Pten-deficient mice (Mx1-Cre+Ptenfl/fl;Rpl24+/+) and in Mx1-Cre+;Ptenfl/fl; 
Rpl24Bst/+ HSCs/MPPs. Exposure times of 5, 10 and 30 minutes are shown. (H-S) Expression of E3 ubiquitin ligases 
that target c-Myc is not reduced in Aarssti/sti HSCs. Expression of (H) Skp2, (I) Btrc, (J) Fbxl3, (K) Fbxl14, (L) 
Fbxo28, (M) Fbxo32, (N) Spop, (O) Kctd2, (P) Trpc4ap, (Q) Trim6, (R) Rlim and (S) Huwe1 in wild-type (+/+) and 
Aarssti/sti (sti/sti) HSCs based on RNA sequencing (n = 3 per genotype). Data represent mean ± standard deviation. 
Statistical significance was assessed using a Student’s t-test (C-F; *P<0.05). Adjusted P values (H-S) did not reach 
the threshold of statistical significance for any of these genes. 
